Archived thesis
UnitedHealth Group
A high-quality compounder bought after a severe drawdown.
Investment case
Quality, and why it was available
UnitedHealth is a high-quality compounder that has been heavily beaten down. Long-term demand for US healthcare should remain substantial, and the insurance model can generate attractive economics at scale. Premium revenue is recurring, and scale confers real advantages in cost of care and in data.
The drawdown is the opportunity and the warning at the same time. Insurers de-rate when medical cost trend runs ahead of pricing, and that gap cannot close within a quarter because premiums are set annually in advance.
Position history: reassessment and re-entry
There was a short period during which I sold the position and later rebuilt it. That sequence is best described as a reassessment followed by a re-entry: I exited the holding, re-examined the situation, and re-established the position.
What determines the outcome
The variable that matters is whether the medical loss ratio stabilises. Revenue growth is not the question for an insurer of this size. Margin is. Operating margin recovering toward its historical band would confirm the thesis; continued deterioration alongside further reserve strengthening would break it.
Business economics
Reporting period through Q2 2026
Figures as filed with the SEC, and margins and growth rates calculated from them. Each chart has a data table.
Premiums earned, net
Reported
Quarterly, US$ billions, Q3 2024 to Q2 2026
Filed as premiums earned net. Fourth quarters are derived as the fiscal-year total less the other three quarters, since filings report no standalone Q4 figure.
Financial data through Q2 2026. Source: SEC filings (opens in a new tab)
Data table: Premiums earned, net
| Period | Premiums earned, net |
|---|---|
| Q3 2024 | $77.4B |
| Q4 2024 | $76.5B |
| Q1 2025 | $86.5B |
| Q2 2025 | $87.9B |
| Q3 2025 | $89.0B |
| Q4 2025 | $88.8B |
| Q1 2026 | $87.6B |
| Q2 2026 | $87.0B |
Total revenue
Reported
Quarterly, US$ billions, Q3 2024 to Q2 2026
Filed as revenues. Fourth quarters are derived as the fiscal-year total less the other three quarters, since filings report no standalone Q4 figure.
Financial data through Q2 2026. Source: SEC filings (opens in a new tab)
Data table: Total revenue
| Period | Total revenue |
|---|---|
| Q3 2024 | $101B |
| Q4 2024 | $101B |
| Q1 2025 | $110B |
| Q2 2025 | $112B |
| Q3 2025 | $113B |
| Q4 2025 | $113B |
| Q1 2026 | $112B |
| Q2 2026 | $112B |
Operating margin
Calculated from reported figures
Quarterly, percent, Q3 2024 to Q2 2026
Calculated as operating income divided by revenue, both as filed.
Financial data through Q2 2026. Source: SEC filings (opens in a new tab)
Data table: Operating margin
| Period | Operating margin |
|---|---|
| Q3 2024 | 8.6% |
| Q4 2024 | 7.7% |
| Q1 2025 | 8.3% |
| Q2 2025 | 4.6% |
| Q3 2025 | 3.8% |
| Q4 2025 | 0.3% |
| Q1 2026 | 8.0% |
| Q2 2026 | 7.1% |
Diluted EPS
Reported
Quarterly, US$ per share, Q3 2024 to Q2 2026
Filed as earnings per share diluted. Fourth-quarter EPS is not shown: it is reported only within annual results, and annual EPS less three quarters is not a valid per-share figure because the share count changes.
Financial data through Q2 2026. Source: SEC filings (opens in a new tab)
Data table: Diluted EPS
| Period | Diluted EPS |
|---|---|
| Q3 2024 | $6.51 |
| Q4 2024 | Not shown |
| Q1 2025 | $6.85 |
| Q2 2025 | $3.74 |
| Q3 2025 | $2.59 |
| Q4 2025 | Not shown |
| Q1 2026 | $6.90 |
| Q2 2026 | $6.04 |
Risks and thesis invalidation
The thesis argues the case against itself in Quality, and why it was available and What determines the outcome.
Related decisions
Sources and revisions
- Company filings: SEC EDGAR (opens in a new tab), through Q2 2026
- Holdings snapshot: October 16, 2026
- The analysis and views are Isaac Toffel's own.
Text revisions: Aug 27, 2026 · Aug 20, 2026.